Abstract #3060

The impact of naproxen on Cerebral Blood Flow in preclinical Alzheimer’s disease

Safa Sanami^1,2, Brittany N Intzandt³, Julia Huck¹, PREVENT-AD Research Group⁴, and Claudine J Gauthier^2,5,6

¹Physics, Concordia University, Montreal, QC, Canada, ²Centre de Recherche de l’Institut de Cardiologie de Montr´eal, Montreal, QC, Canada, ³Sunnybrook Research Institute, Toronto, ON, Canada, ⁴Douglas Mental Health Institute, Montreal, QC, Canada, ⁵Concordia University, Montreal, QC, Canada, ⁶PERFORM Centre, Concordia University, Montreal, QC, Canada

Synopsis

Keywords: Data Processing, Alzheimer's DiseaseAlzheimer’s Disease (AD) is the most common form of dementia and displays a long preclinical phase. The use of non-steroidal anti-inflammatory drugs (NSAIDs) in this phase has a protective effect and decreases the risk of developing AD cross-sectionally. However, the effects of NSAIDs therapy long-term on cerebral hemodynamics in this early phase is unclear. This is the first study to assess whether longitudinal use of NSAIDs (i.e., naproxen) has an impact on cerebral blood flow, and whether this is associated with a change in cognition and/or cerebrospinal fluid markers.

How to access this content:

For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.

After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.

After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.

Click here for more information on becoming a member.